title: Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters.
abstract: Because the prognosis of patients with pancreatic cancer is very poor, development of a novel approach for treatment of this disease is vital. In the present study, we investigated the effect of dendritic cell (DC)-based immunotherapy against established syngeneic hamster pancreatic cancer named HPD1NR. Hamster enriched DCs were prepared from bone marrow (BM) by a culture for 7 days in the presence of mouse GM-CSF and mouse IL-4, and characterized by the expression of specific DC markers (DEC205, DC-SIGN) mRNA using in situ hybridization (ISH). DCs pulsed with tumor lysate and N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) or DCs alone were injected s.c. weekly into HPD1NR-bearing hamsters three times. Tumor growth was significantly inhibited by 82% in hamsters treated with tumor lysate and DOTAP-pulsed DCs when compared with the PBS vehicle-treated group. These findings suggest that DC-based immunotherapy may be a useful approach for the treatment of pancreatic cancers.
authors.affiliation: Growth Factor Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. yaakiyam@gan2.res.ncc.go.jp
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Akiyama
authors.forename: Kouji
authors.initials: K
authors.lastname: Maruyama
authors.forename: Noriko
authors.initials: N
authors.lastname: Nara
authors.forename: Takashi
authors.initials: T
authors.lastname: Hojo
authors.forename: Jin Yan
authors.initials: JY
authors.lastname: Cheng
authors.forename: Toshio
authors.initials: T
authors.lastname: Mori
authors.forename: Robert H
authors.initials: RH
authors.lastname: Wiltrout
authors.forename: Ken
authors.initials: K
authors.lastname: Yamaguchi
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D019496:Cancer Vaccines / Q000276:immunology*; D006224:Cricetinae; D003412:Cricetulus; D017931:DNA Primers / Q000737:chemistry; D003713:Dendritic Cells / Q000276:immunology*; D005229:Fatty Acids, Monounsaturated; D005260:Female; D005456:Fluorescent Dyes; D005822:Genetic Vectors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D007167:Immunotherapy; D017403:In Situ Hybridization; D007279:Injections, Subcutaneous; D018664:Interleukin-12 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D007962:Leukocytes / Q000378:metabolism; D008647:Mesocricetus; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D016133:Polymerase Chain Reaction; D000644:Quaternary Ammonium Compounds; D012333:RNA, Messenger / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D019496:Cancer Vaccines; D017931:DNA Primers; D005229:Fatty Acids, Monounsaturated; D005456:Fluorescent Dyes; D000644:Quaternary Ammonium Compounds; D012333:RNA, Messenger; D011994:Recombinant Proteins; D018664:Interleukin-12; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C070046:1,2-dioleoyloxy-3-(trimethylammonium)propane